Chesapeake Biological to aid heart research

Maryland Watch

January 22, 1998

Chesapeake Biological Laboratories Inc. said yesterday that it has won a contract to formulate, fill and package two experimental fluids being developed for protecting hearts during transplant and bypass surgery.

The contract was struck with LXR Biotechnology Inc. of Richmond, Calif.

The companies declined to disclose financial terms of the deal.

Joseph A. Twist, a CBL spokesman, said the deal calls for the Baltimore-based biotechnology contractor to provide batches of HK-Cardiosol and CP-Cardiosol for clinical trials.

HK-Cardiosol is a liquid developed to prolong the shelf-life of hearts intended for transplantation so that their period of viability can be extended from the current six hours to potentially more than 24 hours.

LXR has regulatory approvals to test the product in the United States and Europe.

CP-Cardiosol is being developed to improve organ protection during heart and lung bypass surgery.

Twist said CBL is hopeful that if clinical trials go well, the agreement will be broadened to CBL manufacturing the products for marketing.

Pub Date: 1/22/98

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.